Keywords: Bayer, EndoCeutics, Females sexual dysfunction, Vaginorm, Johnson & Johnson, Crucell, M&A

Bayer buys rights to “female Viagra” for C$330 million; Johnson & Johnson proceeds with $2.42 billion bid for Crucell

Article | 06 October 2010

Print This

Bayer HealthCare Pharmaceuticals, a unit of Germany’s Bayer (BAY: DE) has entered into an accord with Quebec, Canada-based ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in